Huiqin Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huiqin Xu has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Gaohong Lv
Nanjing University of Chinese Medicine
5 shared publicationsJinfu Lu
Nanjing University of Chinese Medicine
5 shared publicationsAnmei Shu
Department of Basic Medical Science, Jiangsu Vocational College of Medicine, Yancheng, 224005, China; Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Key Laboratory for Efficacy and Safety Evaluation of Traditional Chinese Medicine in Jiangsu Province, Nanjing, 210023, China
4 shared publicationsJing Chen
School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China; Key Laboratory of Efficacy and Safety Evaluation of Traditional Chinese Medicine in Jiangsu Province, Nanjing 210023, China
4 shared publicationsQiu Du
School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China; Department of Pharmacy, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210022, China; Key Laboratory of Efficacy and Safety Evaluation of Traditional Chinese Medicine in Jiangsu Province, Nanjing 210023, China
4 shared publicationsYuyan Gao
Nanjing University of Chinese Medicine
4 shared publications
Latest Publications
- 22 July 2023
- Published by Springer Nature in Current Medical Science
- Vol. 43 (4) , 668-678
Catalpol Prevents Glomerular Angiogenesis Induced by Advanced Glycation End Products via Inhibiting Galectin-3
Objective The main characteristics of diabetic nephropathy (DN) at the early stage are abnormal angiogenesis of glomerular endothelial cells (GECs) and macrophage infiltration. Galectin-3 plays a pivotal role in the pathogenesis of DN via binding with its ligand, advanced glycation end products (AGEs). Catalpol, an iridoid glucoside extracted from Rehmannia glutinosa, has been found to ameliorate vascular inflammation, reduce endothelial permeability, and protect against endothelial damage in diabetic milieu. However, little is known about whether catalpol could exert an anti-angiogenesis and anti-inflammation effect induced by AGEs. Methods Mouse GECs (mGECs) and RAW 264.7 macrophages were treated with different concentrations of AGEs (0, 50, 100, 200 and 400 µg/mL) for different time (0, 6, 12, 24 and 48 h) to determine the optimal concentration of AGEs and treatment time. Cells were treated with catalpol (10 µmol/L), GB1107 (1 µmol/L, galectin-3 inhibitor), PX-478 (50 µmol/L, HIF-1α inhibitor), adenovirus-green fluorescent protein (Ad-GFP) [3×107 plaque-forming unit (PFU)/mL] or Ad-galectin-3-GFP (2×108 PFU/mL), which was followed by incubation with 50 µg/mL AGEs. The levels of galectin-3, vascular endothelial growth factor A (VEGFA) and pro-angiogenic factors angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), tunica interna endothelial cell kinase-2 (Tie-2) were detected by enzymelinked immunosorbent assay (ELISA). Cell counting kit-8 (CCK-8) assay was used to evaluate the proliferation of these cells. The expression levels of galectin-3, vascular endothelial growth factor receptor 1 (VEGFR1), VEGFR2, and hypoxia-inducible factor-1α (HIF-1α) in mGECs and those of galectin-3 and HIF-1α in RAW 264.7 macrophages were detected by Western blotting and immunofluorescence (IF) staining. The rat DN model was established. Catalpol (100 mg/kg) or GB1107 (10 mg/kg) was administered intragastrically once a day for 12 weeks. Ad-galectin-3-GFP (6×107 PFU/mL, 0.5 mL) or Ad-GFP (6×106 PFU/mL, 0.5 mL) was injected into the tail vein of rats 48 h before the sacrifice of the animals. The expression of galectin-3, VEGFR1, VEGFR2, and HIF-1α in renal cortices was analyzed by Western blotting. The expression of galectin-3, F4/80 (a macrophage biomarker), and CD34 (an endothelium biomarker) in renal cortices was detected by IF staining, and collagen accumulation by Masson staining. Results The expression levels of galectin-3 and VEGFA were significantly higher in mGECs and RAW 264.7 macrophages treated with 50 µg/mL AGEs for 48 h than those in untreated cells. Catalpol and GB1107 could block the AGEs-induced proliferation of mGECs and RAW 264.7 macrophages. Over-expression of galectin-3 was found to reduce the inhibitory effect of catalpol on the proliferation of cells. Catalpol could significantly decrease the levels of Ang-1, Ang-2 and Tie-2 released by AGEs-treated mGECs, which could be reversed by over-expression of galectin-3. Catalpol could significantly inhibit AGEs-induced expression of galectin-3, HIF-1α, VEGFR1, and VEGFR2 in mGECs. The inhibitory effect of catalpol on galectin-3 in AGEs-treated mGECs was impaired by PX-478. Moreover, catalpol attenuated the AGEs-activated HIF-1α/galectin-3 pathway in RAW 264.7 macrophages, which was weakened by PX-478. Additionally, catalpol significantly inhibited the expression of galectin-3, macrophage infiltration, collagen accumulation, and angiogenesis in the kidney of diabetic rats. Over-expression of galectin-3 could antagonize these inhibitory effects of catalpol. Conclusion Catalpol prevented the angiogenesis of mGECs and macrophage proliferation via inhibiting galectin-3. It could prevent the progression of diabetes-induced renal damage.
- 22 July 2023
- Published by Springer Nature in Current Medical Science
- Vol. 43 (4) , 668-678
Catalpol Prevents Glomerular Angiogenesis Induced by Advanced Glycation End Products via Inhibiting Galectin-3
Objective The main characteristics of diabetic nephropathy (DN) at the early stage are abnormal angiogenesis of glomerular endothelial cells (GECs) and macrophage infiltration. Galectin-3 plays a pivotal role in the pathogenesis of DN via binding with its ligand, advanced glycation end products (AGEs). Catalpol, an iridoid glucoside extracted from Rehmannia glutinosa, has been found to ameliorate vascular inflammation, reduce endothelial permeability, and protect against endothelial damage in diabetic milieu. However, little is known about whether catalpol could exert an anti-angiogenesis and anti-inflammation effect induced by AGEs. Methods Mouse GECs (mGECs) and RAW 264.7 macrophages were treated with different concentrations of AGEs (0, 50, 100, 200 and 400 µg/mL) for different time (0, 6, 12, 24 and 48 h) to determine the optimal concentration of AGEs and treatment time. Cells were treated with catalpol (10 µmol/L), GB1107 (1 µmol/L, galectin-3 inhibitor), PX-478 (50 µmol/L, HIF-1α inhibitor), adenovirus-green fluorescent protein (Ad-GFP) [3×107 plaque-forming unit (PFU)/mL] or Ad-galectin-3-GFP (2×108 PFU/mL), which was followed by incubation with 50 µg/mL AGEs. The levels of galectin-3, vascular endothelial growth factor A (VEGFA) and pro-angiogenic factors angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), tunica interna endothelial cell kinase-2 (Tie-2) were detected by enzymelinked immunosorbent assay (ELISA). Cell counting kit-8 (CCK-8) assay was used to evaluate the proliferation of these cells. The expression levels of galectin-3, vascular endothelial growth factor receptor 1 (VEGFR1), VEGFR2, and hypoxia-inducible factor-1α (HIF-1α) in mGECs and those of galectin-3 and HIF-1α in RAW 264.7 macrophages were detected by Western blotting and immunofluorescence (IF) staining. The rat DN model was established. Catalpol (100 mg/kg) or GB1107 (10 mg/kg) was administered intragastrically once a day for 12 weeks. Ad-galectin-3-GFP (6×107 PFU/mL, 0.5 mL) or Ad-GFP (6×106 PFU/mL, 0.5 mL) was injected into the tail vein of rats 48 h before the sacrifice of the animals. The expression of galectin-3, VEGFR1, VEGFR2, and HIF-1α in renal cortices was analyzed by Western blotting. The expression of galectin-3, F4/80 (a macrophage biomarker), and CD34 (an endothelium biomarker) in renal cortices was detected by IF staining, and collagen accumulation by Masson staining. Results The expression levels of galectin-3 and VEGFA were significantly higher in mGECs and RAW 264.7 macrophages treated with 50 µg/mL AGEs for 48 h than those in untreated cells. Catalpol and GB1107 could block the AGEs-induced proliferation of mGECs and RAW 264.7 macrophages. Over-expression of galectin-3 was found to reduce the inhibitory effect of catalpol on the proliferation of cells. Catalpol could significantly decrease the levels of Ang-1, Ang-2 and Tie-2 released by AGEs-treated mGECs, which could be reversed by over-expression of galectin-3. Catalpol could significantly inhibit AGEs-induced expression of galectin-3, HIF-1α, VEGFR1, and VEGFR2 in mGECs. The inhibitory effect of catalpol on galectin-3 in AGEs-treated mGECs was impaired by PX-478. Moreover, catalpol attenuated the AGEs-activated HIF-1α/galectin-3 pathway in RAW 264.7 macrophages, which was weakened by PX-478. Additionally, catalpol significantly inhibited the expression of galectin-3, macrophage infiltration, collagen accumulation, and angiogenesis in the kidney of diabetic rats. Over-expression of galectin-3 could antagonize these inhibitory effects of catalpol. Conclusion Catalpol prevented the angiogenesis of mGECs and macrophage proliferation via inhibiting galectin-3. It could prevent the progression of diabetes-induced renal damage.
- Open Access
- 21 March 2022
- Published by Springer Nature in Research Square
Catalpol prevents glomerular angiogenesis induced by advanced glycation end products via inhibiting Galectin-3
Objectives: The main characteristics of Diabetic Nephropathy (DN) at the early stage is abnormal angiogenesis of glomerular endothelial cells and macrophage infiltration. Galectin-3 plays a pivotal role in the pathogenesis of DN via binding with its ligand, Advanced Glycation End products (AGEs). Catalpol (Cat.), an iridoid glucoside extracted fromRehmannia glutinosa, has been found to ameliorate vascular inflammation, reduce endothelial permeability and protect endothelial damage upon diabetic milieu. However, little is known about whether Cat. could exert anti-angiogenesis and anti-inflammation effect induced by AGEs. Methods:The anti-angiogenic mechanisms of Cat. were examined by incubating mouse glomerular endothelial cells (mGECs) and RAW 264.7 macrophages induced by AGEs. The expression of Galectin-3 and correlated molecules were also detected in diabetic rats treated with Cat.Key findings: We observed that Galectin-3/Hypoxia-inducible factor-1(HIF-1α)was activated by AGEs in mGECs and RAW 264.7 macrophages, catalpol significantly inhibited the proliferation of the mGECs and RAW 264.7 macrophages in vitro.Meanwhile, it also ameliorateddiabetes-induced renal damage via inhibiting Galectin-3/VEGF/HIF-1α pathways in vivo.Conclusions: Altogether, our findings demonstrated that Cat. prevent the angiogenesis of mGECs and macrophages proliferation via inhibiting Galectin-3. We suggest that Cat.contributes to block the pathogenic development of diabetes-induced renal damage.
- 21 March 2022
- Published by Springer Nature in Research Square
Open AccessCatalpol prevents glomerular angiogenesis induced by advanced glycation end products via inhibiting Galectin-3
Objectives: The main characteristics of Diabetic Nephropathy (DN) at the early stage is abnormal angiogenesis of glomerular endothelial cells and macrophage infiltration. Galectin-3 plays a pivotal role in the pathogenesis of DN via binding with its ligand, Advanced Glycation End products (AGEs). Catalpol (Cat.), an iridoid glucoside extracted fromRehmannia glutinosa, has been found to ameliorate vascular inflammation, reduce endothelial permeability and protect endothelial damage upon diabetic milieu. However, little is known about whether Cat. could exert anti-angiogenesis and anti-inflammation effect induced by AGEs. Methods:The anti-angiogenic mechanisms of Cat. were examined by incubating mouse glomerular endothelial cells (mGECs) and RAW 264.7 macrophages induced by AGEs. The expression of Galectin-3 and correlated molecules were also detected in diabetic rats treated with Cat.Key findings: We observed that Galectin-3/Hypoxia-inducible factor-1(HIF-1α)was activated by AGEs in mGECs and RAW 264.7 macrophages, catalpol significantly inhibited the proliferation of the mGECs and RAW 264.7 macrophages in vitro.Meanwhile, it also ameliorateddiabetes-induced renal damage via inhibiting Galectin-3/VEGF/HIF-1α pathways in vivo.Conclusions: Altogether, our findings demonstrated that Cat. prevent the angiogenesis of mGECs and macrophages proliferation via inhibiting Galectin-3. We suggest that Cat.contributes to block the pathogenic development of diabetes-induced renal damage.
- 1 October 2021
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 348, 109625
Catalpol ameliorates endothelial dysfunction and inflammation in diabetic nephropathy via suppression of RAGE/RhoA/ROCK signaling pathway
- 1 October 2021
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 348, 109625
Catalpol ameliorates endothelial dysfunction and inflammation in diabetic nephropathy via suppression of RAGE/RhoA/ROCK signaling pathway
- 1 September 2021
- Published by Elsevier in Fitoterapia
- Vol. 153, 104950
The indole alkaloids from the roots of Isatidis Radix
- 1 September 2021
- Published by Elsevier in Fitoterapia
- Vol. 153, 104950
The indole alkaloids from the roots of Isatidis Radix
- 1 May 2021
- Published by Elsevier in Life Sciences
- Vol. 272, 118808
Loganin alleviates macrophage infiltration and activation by inhibiting the MCP-1/CCR2 axis in diabetic nephropathy
- 1 May 2021
- Published by Elsevier in Life Sciences
- Vol. 272, 118808
Loganin alleviates macrophage infiltration and activation by inhibiting the MCP-1/CCR2 axis in diabetic nephropathy
- 1 February 2021
- Published by Elsevier in Life Sciences
- Vol. 267, 118881
Catalpol ameliorates diabetes-induced testicular injury and modulates gut microbiota
- 1 February 2021
- Published by Elsevier in Life Sciences
- Vol. 267, 118881
Catalpol ameliorates diabetes-induced testicular injury and modulates gut microbiota
- Open Access
- 2 December 2020
- Published by Wiley in Journal of Diabetes Research
- Vol. 2020, 1-15
Radix Rehmanniae and Corni Fructus against Diabetic Nephropathy via AGE-RAGE Signaling Pathway
Background and Aims. Radix Rehmanniae and Corni Fructus (RC) have been widely applied to treat diabetic nephropathy (DN) for centuries. But the mechanism of how RC plays the therapeutic role against DN is unclear as yet. Methods. The information about RC was obtained from a public database. The active compounds of RC were screened by oral bioavailability (OB) and drug-likeness (DL). Gene ontology (GO) analysis was performed to realize the key targets of RC, and an active compound-potential target network was created. The therapeutic effects of RC active compounds and their key signal pathways were preliminarily probed via network pharmacology analysis and animal experiments. Results. In this study, 29 active compounds from RC and 64 key targets related to DN were collected using the network pharmacology method. The pathway enrichment analysis showed that RC regulated advanced glycosylation end product (AGE-) RAGE and IL-17 signaling pathways to treat DN. The animal experiments revealed that RC significantly improved metabolic parameters, inflammation renal structure, and function to protect the kidney against DN. Conclusions. The results revealed the relationship between multicomponents and multitargets of RC. The administratiom of RC might remit the DM-induced renal damage through the AGE-RAGE signaling pathway to improve metabolic parameters and protect renal structure and function.
- 2 December 2020
- Published by Wiley in Journal of Diabetes Research
- Vol. 2020, 1-15
Open AccessRadix Rehmanniae and Corni Fructus against Diabetic Nephropathy via AGE-RAGE Signaling Pathway
Background and Aims. Radix Rehmanniae and Corni Fructus (RC) have been widely applied to treat diabetic nephropathy (DN) for centuries. But the mechanism of how RC plays the therapeutic role against DN is unclear as yet. Methods. The information about RC was obtained from a public database. The active compounds of RC were screened by oral bioavailability (OB) and drug-likeness (DL). Gene ontology (GO) analysis was performed to realize the key targets of RC, and an active compound-potential target network was created. The therapeutic effects of RC active compounds and their key signal pathways were preliminarily probed via network pharmacology analysis and animal experiments. Results. In this study, 29 active compounds from RC and 64 key targets related to DN were collected using the network pharmacology method. The pathway enrichment analysis showed that RC regulated advanced glycosylation end product (AGE-) RAGE and IL-17 signaling pathways to treat DN. The animal experiments revealed that RC significantly improved metabolic parameters, inflammation renal structure, and function to protect the kidney against DN. Conclusions. The results revealed the relationship between multicomponents and multitargets of RC. The administratiom of RC might remit the DM-induced renal damage through the AGE-RAGE signaling pathway to improve metabolic parameters and protect renal structure and function.
- 1 September 2020
- Published by Elsevier in Life Sciences
- Vol. 257, 118120
Study on the inhibitive effect of Catalpol on diabetic nephropathy
- 1 September 2020
- Published by Elsevier in Life Sciences
- Vol. 257, 118120
Study on the inhibitive effect of Catalpol on diabetic nephropathy
- Open Access
- 12 March 2019
- Published by Wiley in IUBMB Life
- Vol. 71 (9) , 1268-1283
Catalpol ameliorates advanced glycation end product‐induced dysfunction of glomerular endothelial cells via regulating nitric oxide synthesis by inducible nitric oxide synthase and endothelial nitric oxide synthase
Catalpol (Cat.) is an iridoid glucoside extracted from the root of Rehmannia glutinosa Libosch. In this study, we investigated whether Cat. could protect the mouse glomerular endothelial cells against the deleterious effect induced by advanced glycation end products (AGEs) and explored potential mechanisms. We found that 10 μM Cat. showed a protective effect on dead cells stimulated by AGEs. Cat. significantly decreased the expression of p‐NF‐κBp65 and inducible nitric oxide synthase (iNOS) and increased the expression of phosphorylated‐endothelial nitric oxide synthase (p‐eNOS; Ser1177), PI3K, p‐Akt (Thr308), and total‐Akt. Moreover, Cat. restored the integrity of glomerular endothelial barrier by increasing endothelial tight gap junction protein and ameliorated the endothelial hyperpermeability induced by AGEs via modulating the nitric oxide (NO) production. Additionally, Cat. attenuated the massive release of NO induced by AGEs, inhibiting the macrophage infiltration by modulating the NO production, accompanied by the decrease in the release of monocyte chemoattractant protein‐1 and intercellular cell adhesion molecule‐1 in vitro. Therefore, Cat. ameliorated AGEs‐induced endothelial dysfunction via inhibiting the NF‐κB/iNOS pathway and activating the PI3K/Akt/eNOS pathway. © 2019 IUBMB Life, 71(9):1268–1283, 2019
- 12 March 2019
- Published by Wiley in IUBMB Life
- Vol. 71 (9) , 1268-1283
Open AccessCatalpol ameliorates advanced glycation end product‐induced dysfunction of glomerular endothelial cells via regulating nitric oxide synthesis by inducible nitric oxide synthase and endothelial nitric oxide synthase
Catalpol (Cat.) is an iridoid glucoside extracted from the root of Rehmannia glutinosa Libosch. In this study, we investigated whether Cat. could protect the mouse glomerular endothelial cells against the deleterious effect induced by advanced glycation end products (AGEs) and explored potential mechanisms. We found that 10 μM Cat. showed a protective effect on dead cells stimulated by AGEs. Cat. significantly decreased the expression of p‐NF‐κBp65 and inducible nitric oxide synthase (iNOS) and increased the expression of phosphorylated‐endothelial nitric oxide synthase (p‐eNOS; Ser1177), PI3K, p‐Akt (Thr308), and total‐Akt. Moreover, Cat. restored the integrity of glomerular endothelial barrier by increasing endothelial tight gap junction protein and ameliorated the endothelial hyperpermeability induced by AGEs via modulating the nitric oxide (NO) production. Additionally, Cat. attenuated the massive release of NO induced by AGEs, inhibiting the macrophage infiltration by modulating the NO production, accompanied by the decrease in the release of monocyte chemoattractant protein‐1 and intercellular cell adhesion molecule‐1 in vitro. Therefore, Cat. ameliorated AGEs‐induced endothelial dysfunction via inhibiting the NF‐κB/iNOS pathway and activating the PI3K/Akt/eNOS pathway. © 2019 IUBMB Life, 71(9):1268–1283, 2019
- 11 April 2016
- Published by Springer Nature in Human Cell
- Vol. 29 (4) , 148-154
Effect of morroniside on glomerular mesangial cells through AGE–RAGE pathway
Diabetes mellitus is an endocrine and metabolic disease characterized by high blood glucose. Diabetic nephropathy (DN) is one of the most typical diabetic complications. Cornus officinalis is a type of traditional Chinese medicine that replenishes the liver and kidney. Morroniside is one of the main characteristic components of C. officinalis. In this study, an in vitro model for simulating DN damage was established by stimulating rat glomerular mesangial cells by the advanced glycation end products. The protective mechanism and effect of morroniside in regulating receptor for advanced glycation end products signaling pathway in DN was investigated to provide experimental evidence for the prevention and treatment of DN.
- 11 April 2016
- Published by Springer Nature in Human Cell
- Vol. 29 (4) , 148-154
Effect of morroniside on glomerular mesangial cells through AGE–RAGE pathway
Diabetes mellitus is an endocrine and metabolic disease characterized by high blood glucose. Diabetic nephropathy (DN) is one of the most typical diabetic complications. Cornus officinalis is a type of traditional Chinese medicine that replenishes the liver and kidney. Morroniside is one of the main characteristic components of C. officinalis. In this study, an in vitro model for simulating DN damage was established by stimulating rat glomerular mesangial cells by the advanced glycation end products. The protective mechanism and effect of morroniside in regulating receptor for advanced glycation end products signaling pathway in DN was investigated to provide experimental evidence for the prevention and treatment of DN.